Skip to main content
. 2022 May 13;6(3):229–242. doi: 10.1177/24741264221080376

Figure 2.

Figure 2.

Choroidal neovascular membranes after treatment with ranibizumab (same patient as in Figure 1). (A) Infrared and (B) cross-sectional B-scan on spectral-domain optical coherence tomography (OCT). En face (C) OCT and (D) OCT angiography (OCTA) images with (E) cross-sectional B-scan OCT with flow overlay. The images depict resolution of the subretinal hyperreflective material and subretinal fluid along with shrinkage of the vascular network based on OCTA.